Skip to main content
PEPG
NASDAQ Life Sciences

PepGen's DM1 Drug Cleared for Highest Dose; Cash Runway Extended into Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.1
Mkt Cap
$136.955M
52W Low
$1.01
52W High
$7.8
52W Position info
108% above low
Off High info
73% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PEPG has more than doubled off its 52-week low of $1.01.

Summary

PepGen's PGN-EDODM1 cleared to advance to the highest dose in its Phase 2 DM1 trial, with pivotal data due in November. Cash runway extended into Q4 2027.


Key Events · Product Development and Regulatory · PEPG

  • DSMB Clears Highest Dose Cohort

    An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study into the 12.5 mg/kg cohort with no protocol changes, and also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.

  • 10 mg/kg Cohort Fully Enrolled

    7 of 8 participants have completed dosing in the 10 mg/kg cohort; data from this cohort is expected in November 2026.

  • Cash Runway Extended into Q4 2027

    Cash, cash equivalents, and marketable securities totaled $117.2 million as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027.

  • Q2 2026 Financial Results

    Net loss was $17.8 million ($0.26 per share), with R&D expenses of $12.5 million and G&A of $6.4 million, both down from the prior year period.


Analysis · PEPG · Life Sciences

An independent safety board cleared PepGen's lead DM1 drug, PGN-EDODM1, to advance to the highest planned dose in its Phase 2 trial after reviewing data from the fully enrolled 10 mg/kg cohort. The DSMB also approved dose escalation in the open-label extension study. This removes a key clinical risk and keeps the program on track for a pivotal data readout in November. The company also reported a cash position of $117.2 million, extending its runway into the fourth quarter of 2027, which reduces near-term financing overhang.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PEPG was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137M. The 52-week trading range was $1.01 to $7.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PEPG - Latest Insights

PEPG
Nov 11, 2026, 10:22 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $5.35
Real-time Price: $4.58 info
Change: -$0.7652 (-14%) info
Market Cap: $301.979M info
PEPG
Nov 10, 2026, 4:23 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $4.58 info
Change: -$0.3017 (-6%) info
Market Cap: $301.979M info
PEPG
Nov 10, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $4.58 info
Change: +$2.18 (+91%) info
Market Cap: $301.979M info
PEPG
Nov 10, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $4.58 info
Change: +$2.18 (+91%) info
Market Cap: $301.979M info
PEPG
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $4.58 info
Change: +$1.78 (+64%) info
Market Cap: $301.979M info